The Massive Grocery Chain Recalling Sausage And Hummus In Several States
All of the hummuses recalled were of the 10-ounce size and would have been purchased at Fred Meyer and QFC stores in Alaska, Oregon, Washington, and Idaho. The following flavors have been recalled: King Harvest Roasted Garlic, Lemon, Jalapeño, Chipotle, Balsamic, Spinach, Classic, Sundried Tomato, Black Olive, Sesame, Roasted Pepper, and Toasted Onion. Kroger advises anyone who has purchased the affected King Harvest hummuses to return them to the store for a full refund and to not ingest any of the potentially contaminated product.
Also, on February 1, Kroger issued a recall on the DJ's Hot Jalapeño Boudain in the 12-ounce size, DJ's Boudain Sausage in the 24-ounce size, and DJ's Boudain Sausage in the 16-ounce size. The "boudain" sausages, which are a type of Cajun boudin sausages, have been recalled because of potential contamination by pieces of a pen. According to the Kroger website, the recall affects Texas and Louisiana locations of the popular Kroger grocery store chain. The products can be returned to the store for a refund and should not be consumed to avoid potential illness or injury.
Read more: 13 Ways To Help Save Money At The Grocery Store
It's important to remain vigilant when it comes to products purchased at the grocery store. Accidents happen, and large-scale production of food and grocery items is bound to result in some slip ups here and there. It's the same assumed risk that comes with anything, just like riding a bike, ordering take out, or getting a coffee at your favorite café. Many grocery store chains and brands publish recalls on products they carry on their website. You can also consult the U.S. Food and Drug Administration (FDA) website for additional information. If you suspect or become aware of a recalled product in your fridge or kitchen, reach out to the store where you purchased the item and ask about a refund.
Of course, make sure you do not consume any of the product, either. Not all food recalls necessarily mean you have food infected with a horrible bacteria or contaminant. Sometimes, like with Kroger's recall of the King Harvest Hummus and the DJ's Boudain Sausage, recalls are due to possible foreign objects. If a company is recalling a product, it can be out of an abundance of caution rather than a confirmed contamination and, in that instance, is a testament to the brand's safety and quality standards. Consult the FDA's recall classifications to learn more about what class I, II, and III recalls are and what they mean for you.
Read the original article on Tasting Table.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
29 minutes ago
- Yahoo
Medical device industry says future MDUFA hikes unsustainable
This story was originally published on MedTech Dive. To receive daily news and insights, subscribe to our free daily MedTech Dive newsletter. Medical device companies advocated against future increases to user fees at a public hearing Monday for the next medical device user fee amendments. Meanwhile, Food and Drug Administration leaders, facing congressional budget cuts, made a case for more user fees, emphasizing the importance of the program. The five-year agreement determines the amount the FDA can raise from the medtech industry to supplement congressional appropriations. In the current MDUFA program, which ends in September 2027, the FDA's device center negotiated a boost in user fee funding in exchange for meeting certain review timelines and staffing levels. The next agreement would take effect in October 2027 and run through 2032. Michelle Tarver, director of the FDA's Center for Devices and Radiological Health, said the FDA 'requires sustained and increased investment by the medical device industry' to meet its goals. The device leader added that 'holding steady does not lead to excellence — it leads to mediocrity.' However, device industry lobbyists at the meeting indicated a preference for few changes. 'Each MDUFA cycle included significant resources and investments, including increasing the number of [full-time employees] to support the program,' said Janet Trunzo, senior executive vice president of technology and regulatory affairs for AdvaMed. 'Now that we have approached nearly 25 years … of user fee programs for medical devices, we are now in a position of merely fine-tuning the current program.' Mark Leahey, CEO of the Medical Device Manufacturers Association, called for the process to return 'back to the basics' in comments on Monday. Leahey said the funds from MDUFA should go to reviewers and medical officers, and added that the industry wants more visibility as to where the funds are going and 'where people are right now, realizing there's been some attrition over the last six months.' Citing the latest user fee rates, Leahey said more than $427 million in fees were authorized for fiscal year 2026. 'We have to realize the size and scope of the investments here,' he said. 'And this is not a sustainable pathway.' The meeting kicked off a process where the FDA will seek public comment through Sept. 4, before beginning negotiations with industry. When a final agreement is reached, the FDA will present it to Congress, which must approve the next MDUFA program. The negotiations come during a period of uncertainty, where several leaders have left the FDA under Health and Human Services Secretary Robert F. Kennedy Jr. The Trump administration's slashing of probationary FDA employees in February — followed by rehiring some staffers, and then more firings in April — raised questions about whether the FDA's user fees programs could be at risk. FDA Commissioner Marty Makary has suggested lowering user fees for prescription drugs; however, he has not indicated any major changes to medical device fees, referring to MDUFA as 'the best of all the user fee arrangements' during the meeting. Patient advocates call for more fees, transparency While industry pushed back against further fee increases, patient groups called for more fees to offset federal budget cuts to the FDA. Diana Zuckerman, president of the National Center for Health Research, said that given recent cuts in FDA staffing and the importance of speedy device reviews, 'it's inevitable that improving quality requires increasing the fees.' Zuckerman said that while she would like to see Congress provide enough appropriations for the FDA's device center, 'we want to make sure that there's funding for everything that's needed, and, unfortunately, appropriations isn't making that possible.' Zuckerman also called for user fees to be used for postmarket device safety, as well as for more transparency during the negotiation process, positions that were supported by other patient advocates during the meeting. In the past, user fee negotiations have been behind closed doors, and patients, consumers and health professionals have not been able to join or observe the meetings, Zuckerman said. In the last round of negotiations, the FDA also faced scrutiny for not publishing meeting minutes from its conversations with industry in a timely fashion. 'At the very least, we should have access to remotely watch those negotiations, instead of just depending on minutes that are often vague or very delayed so that stakeholders have no opportunity for meaningful input,' said Tess Robertson-Neel, on behalf of the Patient, Consumer, & Public Health Coalition, a group of more than two dozen nonprofits. Robertson-Neel added that user fees should be increased, and the FDA should focus on being 'more patient-centered and transparent and less cozy with industry.' Alexander Naum, policy manager for Generation Patient, a nonprofit representing young adults living with chronic medical conditions, said that user fees must increase and the next MDUFA agreement should include clear postmarket device safety performance goals. He also asked for the FDA to commit funds to expanding its program for tracking medical device adverse events. Naum cited a statistic that the FDA receives more than 2 million reports annually of suspected device malfunctions, serious injuries or deaths. 'So many of us rely on medical devices for our survival,' Naum said. 'Many of these devices present the potential of unexpected adverse events.' Recommended Reading FDA schedules first public MDUFA VI meeting ahead of negotiations Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
an hour ago
- Yahoo
Mom, 58, Used a 'Miracle' GLP to 'Be Thin' for Her Son's Wedding. She Claims It Made Her So Sick She Almost Missed the Big Day
NEED TO KNOW Ali Eastburn, a 58-year-old mom from Nashville, was struggling with losing weight after menopause She turned to the GLP-1 medication Ozempic because she wanted 'to be thin' for her son's upcoming wedding, but when her weight loss stalled, she said she increased her Ozempic dose — after which her appendix burst A rep for the manufacturer told PEOPLE, "Novo Nordisk remains confident in the benefit-risk profile of our GLP-1 medicines, when used consistent with their indications and product labeling"A mom who started taking Ozempic to drop weight before her son's wedding nearly missed the big day after her appendix burst. She claimed the medical emergency was caused by the medication, which she said 'almost killed me.' Ali Eastburn, 58, struggled with her 'post-menopausal' weight for years. 'My whole metabolism just changed and I had tried everything to lose weight,' the Nashville mom said, according to the Daily Mail. Eastburn, who was a size 16 before starting Ozempic, worried about how she might look in the photos for her son Chase's upcoming wedding. In April, her doctor prescribed her the weight loss drug. Ozempic and others in its class (the active agent, semaglutide, is marketed under the brand names Wegovy and Mounjaro) impact satiety. While Ozempic is approved by the FDA for people with type 2 diabetes and not formally approved for weight loss, it has become a trendy way to shed extra pounds. A Novo Nordisk spokesperson told PEOPLE: "Semaglutide has been extensively examined in robust clinical development programs, large real-world-evidence studies and has cumulatively over 33 million patient years of exposure." They continued, "Semaglutide's efficacy and safety have been extensively demonstrated in people with obesity/overweight with robust evidence for improving health outcomes. Semaglutide has demonstrated improvements in CV death, stroke and myocardial infarction. Novo Nordisk remains confident in the benefit-risk profile of our GLP-1 medicines, when used consistent with their indications and product labeling." Eastburn said, "At first, it seemed like a miracle. The weight was just coming off.' By the start of July, Eastburn had lost 15 lbs. 'I felt better and that there was hope,' she said. But then, her weight loss stalled: 'I knew I had to do something drastic as I was desperate to look better. I didn't want to hate the wedding photos for the rest of my life,' Eastburn said. 'I upped my dose so I could get to my goal of losing 20 lbs.' Eastburn did not clarify whether she consulted with a doctor before increasing her dosage of Ozempic. The FDA warned in 2024 that taking more than the recommended dose of compounded semaglutide could lead to "gastrointestinal effects (e.g., nausea, vomiting, abdominal pain)," as well as "fainting, headache, migraine, dehydration, acute pancreatitis and gallstones." After upping her dose, Eastburn said she felt an immediate impact. 'The first week the nausea was uncontrollable and I had no desire to eat or drink anything,' she said, explaining she felt an 'all-new level' of 'excruciatingly painful' heartburn. Explaining she was 'sick as a dog,' Eastburn said she was dry heaving and fighting the urge to vomit when she went shopping for a dress to wear to the wedding. She said she ended up in the emergency room twice, struggling with nausea and 'violent diarrhea.' Still, she flew from Nashville to Orange County, Calif., on July 15 for the wedding — only to get so ill on the flight that once they landed, 'an ambulance took me to the hospital straight away and I was diagnosed with a burst appendix.' A burst appendix is a medical emergency, according to the Cleveland Clinic, and happens when the appendix becomes inflamed; When it bursts, it sends bacteria throughout your body, risking life-threatening complications. Eastburn spent four days in the hospital, missing Chase's rehearsal dinner. 'I just cried as I felt like it was my fault as I did this to myself. I missed all of this as I wanted to be thin and it broke my heart,' said Eastburn, who nearly missed the wedding. 'We went at the very last minute as I was in so much pain. Sitting on a chair was so painful and I could barely walk. When my son saw me sitting in the front row, he came over and hugged me for the longest time and bawled like a baby,' she said. 'We didn't think I was going to be at the wedding, much less live to tell anyone about it. I didn't care about my size as I was just so proud to be there. It was hard to stand and do the mother-son dance, but I was so grateful,' she said, sharing that while 'I was so swollen and my stomach was so puffy,' her weight 'was the last thing on my mind.' Never miss a story — sign up for to stay up-to-date on the best of what PEOPLE has to offer, from celebrity news to compelling human interest stories. Eastburn claimed the medication caused her health struggle; There have been sporadic case studies that suggest appendicitis could be a potential risk, but there has been no direct link established between the medication and the condition. 'I will never jeopardize or endanger myself again with any drugs to lose weight as that was too close of a call,' Eastburn said. 'I would say think long and hard before taking a GLP-1 as it almost killed me," she claimed. "If you care about your family or people that you love, think about them having to live life without you as it might kill you. Being thin is not worth losing your life.' Read the original article on People
Fox Sports
an hour ago
- Fox Sports
NFL Bans Smelling Salts, Saying They Can Mask Concussion Symptoms
National Football League NFL Bans Smelling Salts, Saying They Can Mask Concussion Symptoms Published Aug. 5, 2025 6:11 p.m. ET share facebook x reddit link The NFL is banning the use of "smelling salts" during games, saying the products aren't proven to be safe and also could mask signs of a concussion. The league sent a memo to teams on Tuesday explaining the decision to ban smelling salts and any other ammonia inhalant during pregame activities, games and halftime on the sideline or locker rooms. "In 2024, the FDA issued a warning to companies that produce commercially available ammonia inhalants (AIs), as well as to consumers about the purchase and use of AIs, regarding the lack of evidence supporting the safety or efficacy of AIs marketed for improving mental alertness or boosting energy," according to the memo obtained by The Associated Press. "The FDA noted potential negative effects from AI use. AIs also have the potential to mask certain neurologic signs and symptoms, including some potential signs of concussion. As a result, the NFL Head, Neck, and Spine Committee recommended prohibiting the use of AIs for any purpose during play in the NFL." San Francisco 49ers tight end George Kittle first disclosed the ban during an interview with NFL Network on Tuesday, adding that he hoped the league would relent and "figure out a middle ground." ADVERTISEMENT That won't happen, according to the memo, which explicitly prohibits any club personnel from providing or supplying products such as ammonia capsules, inhalers, ammonia in a cup, and any form of "smelling salts." Smelling salts and other similar products have been a staple on NFL sidelines for years with many players believing they can provide a sudden jolt of energy or alertness. Reporting by The Associated Press. Want great stories delivered right to your inbox? Create or log in to your FOX Sports account and follow leagues, teams and players to receive a personalized newsletter daily! share
